<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;ff=20250224031514&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;ff=20250224031514&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Mon, 24 Feb 2025 08:15:16 +0000</lastbuilddate>
<pubDate>Sun, 23 Feb 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Rift Valley fever virus coordinates the assembly of a programmable E3 ligase to promote viral replication</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39987918/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 22:S0092-8674(25)00193-X. doi: 10.1016/j.cell.2025.02.008. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39987918/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39987918</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.008>10.1016/j.cell.2025.02.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39987918</guid>
<pubDate>Sun, 23 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Huiling Li</dc:creator>
<dc:creator>Yulan Zhang</dc:creator>
<dc:creator>Guibo Rao</dc:creator>
<dc:creator>Chongtao Zhang</dc:creator>
<dc:creator>Zhenqiong Guan</dc:creator>
<dc:creator>Ziyan Huang</dc:creator>
<dc:creator>Shufen Li</dc:creator>
<dc:creator>Pierre-Yves Lozach</dc:creator>
<dc:creator>Sheng Cao</dc:creator>
<dc:creator>Ke Peng</dc:creator>
<dc:date>2025-02-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Rift Valley fever virus coordinates the assembly of a programmable E3 ligase to promote viral replication</dc:title>
<dc:identifier>pmid:39987918</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.008</dc:identifier>
</item>
<item>
<title>Salt sensitivity of blood pressure: mechanisms and sex-specific differences</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39984695/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>Salt sensitivity of blood pressure (SSBP) is an independent risk factor for cardiovascular disease in individuals with or without hypertension. However, the mechanisms and management of SSBP remain unclear, mainly because the diagnosis of this condition relies on salt loading-depletion protocols that are not feasible in the clinic. The prevalence of hypertension is lower in premenopausal women than in men, but this sex-specific difference is reversed after menopause. Whether excessive SSBP in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Feb 21. doi: 10.1038/s41569-025-01135-0. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Salt sensitivity of blood pressure (SSBP) is an independent risk factor for cardiovascular disease in individuals with or without hypertension. However, the mechanisms and management of SSBP remain unclear, mainly because the diagnosis of this condition relies on salt loading-depletion protocols that are not feasible in the clinic. The prevalence of hypertension is lower in premenopausal women than in men, but this sex-specific difference is reversed after menopause. Whether excessive SSBP in women at any age contributes to this reversal is unknown, but many clinical studies that have rigorously assessed for SSBP using salt loading-depletion protocols have confirmed that SSBP is more prevalent in women than in men, including during premenopausal age. In this Review, we discuss sex-specific mechanisms of SSBP. We describe sex-related differences in renal transporters, hypertensive pregnancy, SSBP in autoimmune disorders and mitogen-activated protein kinase signalling pathways, and highlight limitations and lessons learned from Dahl salt-sensitive rat models.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39984695/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39984695</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01135-0>10.1038/s41569-025-01135-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39984695</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Sepiso K Masenga</dc:creator>
<dc:creator>Nelson Wandira</dc:creator>
<dc:creator>Giuliana Cattivelli-Murdoch</dc:creator>
<dc:creator>Mohammad Saleem</dc:creator>
<dc:creator>Heather Beasley</dc:creator>
<dc:creator>Antentor Hinton</dc:creator>
<dc:creator>Lale A Ertuglu</dc:creator>
<dc:creator>Naome Mwesigwa</dc:creator>
<dc:creator>Thomas R Kleyman</dc:creator>
<dc:creator>Annet Kirabo</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Salt sensitivity of blood pressure: mechanisms and sex-specific differences</dc:title>
<dc:identifier>pmid:39984695</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01135-0</dc:identifier>
</item>
<item>
<title>A nucleosome switch primes hepatitis B virus infection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39983728/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>Chronic hepatitis B virus (HBV) infection is an incurable pathogen responsible for causing liver disease and hepatocellular carcinoma. During the genesis of infection, HBV establishes an independent minichromosome consisting of the viral covalently closed circular DNA (cccDNA) genome and host histones. The viral X gene must be expressed immediately upon infection to induce degradation of the host silencing factor, the Smc5/6 complex. However, the relationship between cccDNA chromatinization and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 16:S0092-8674(25)00102-3. doi: 10.1016/j.cell.2025.01.033. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Chronic hepatitis B virus (HBV) infection is an incurable pathogen responsible for causing liver disease and hepatocellular carcinoma. During the genesis of infection, HBV establishes an independent minichromosome consisting of the viral covalently closed circular DNA (cccDNA) genome and host histones. The viral X gene must be expressed immediately upon infection to induce degradation of the host silencing factor, the Smc5/6 complex. However, the relationship between cccDNA chromatinization and X gene transcription remains poorly understood. By establishing a reconstituted viral minichromosome platform, we found that nucleosome occupancy in cccDNA regulates X transcription. We corroborated these findings in situ and further showed that the chromatin-destabilizing molecule CBL137 inhibits full-length X transcription and HBV infection in primary human hepatocytes. Our results shed light on a long-standing paradox and represent a potential therapeutic approach for the treatment of chronic HBV infection.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39983728/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39983728</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.033>10.1016/j.cell.2025.01.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39983728</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Nicholas A Prescott</dc:creator>
<dc:creator>Tracy Biaco</dc:creator>
<dc:creator>Andrés Mansisidor</dc:creator>
<dc:creator>Yaron Bram</dc:creator>
<dc:creator>Justin Rendleman</dc:creator>
<dc:creator>Sarah C Faulkner</dc:creator>
<dc:creator>Abigail A Lemmon</dc:creator>
<dc:creator>Christine Lim</dc:creator>
<dc:creator>Rachel Tiersky</dc:creator>
<dc:creator>Eralda Salataj</dc:creator>
<dc:creator>Liliana Garcia-Martinez</dc:creator>
<dc:creator>Rodrigo L Borges</dc:creator>
<dc:creator>Lluis Morey</dc:creator>
<dc:creator>Pierre-Jacques Hamard</dc:creator>
<dc:creator>Richard P Koche</dc:creator>
<dc:creator>Viviana I Risca</dc:creator>
<dc:creator>Robert E Schwartz</dc:creator>
<dc:creator>Yael David</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A nucleosome switch primes hepatitis B virus infection</dc:title>
<dc:identifier>pmid:39983728</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.033</dc:identifier>
</item>
<item>
<title>Plasmodesmata act as unconventional membrane contact sites regulating intercellular molecular exchange in plants</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39983675/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>Membrane contact sites (MCSs) are fundamental for intracellular communication, but their role in intercellular communication remains unexplored. We show that in plants, plasmodesmata communication bridges function as atypical endoplasmic reticulum (ER)-plasma membrane (PM) tubular MCSs, operating at cell-cell interfaces. Similar to other MCSs, ER-PM apposition is controlled by a protein-lipid tethering complex, but uniquely, this serves intercellular communication. Combining high-resolution...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 20;188(4):958-977.e23. doi: 10.1016/j.cell.2024.11.034.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Membrane contact sites (MCSs) are fundamental for intracellular communication, but their role in intercellular communication remains unexplored. We show that in plants, plasmodesmata communication bridges function as atypical endoplasmic reticulum (ER)-plasma membrane (PM) tubular MCSs, operating at cell-cell interfaces. Similar to other MCSs, ER-PM apposition is controlled by a protein-lipid tethering complex, but uniquely, this serves intercellular communication. Combining high-resolution microscopy, molecular dynamics, and pharmacological and genetic approaches, we show that cell-cell trafficking is modulated through the combined action of multiple C2 domains transmembrane domain proteins (MCTPs) 3, 4, and 6 ER-PM tethers and phosphatidylinositol-4-phosphate (PI4P) lipid. Graded PI4P amounts regulate MCTP docking to the PM, their plasmodesmata localization, and cell-cell permeability. SAC7, an ER-localized PI4P-phosphatase, regulates MCTP4 accumulation at plasmodesmata and modulates cell-cell trafficking capacity in a cell-type-specific manner. Our findings expand MCS functions in information transmission from intracellular to intercellular cellular activities.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39983675/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39983675</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.034>10.1016/j.cell.2024.11.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39983675</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Jessica Pérez-Sancho</dc:creator>
<dc:creator>Marija Smokvarska</dc:creator>
<dc:creator>Gwennogan Dubois</dc:creator>
<dc:creator>Marie Glavier</dc:creator>
<dc:creator>Sujith Sritharan</dc:creator>
<dc:creator>Tatiana S Moraes</dc:creator>
<dc:creator>Hortense Moreau</dc:creator>
<dc:creator>Victor Dietrich</dc:creator>
<dc:creator>Matthieu P Platre</dc:creator>
<dc:creator>Andrea Paterlini</dc:creator>
<dc:creator>Ziqiang P Li</dc:creator>
<dc:creator>Laetitia Fouillen</dc:creator>
<dc:creator>Magali S Grison</dc:creator>
<dc:creator>Pepe Cana-Quijada</dc:creator>
<dc:creator>Françoise Immel</dc:creator>
<dc:creator>Valerie Wattelet</dc:creator>
<dc:creator>Mathieu Ducros</dc:creator>
<dc:creator>Lysiane Brocard</dc:creator>
<dc:creator>Clément Chambaud</dc:creator>
<dc:creator>Yongming Luo</dc:creator>
<dc:creator>Priya Ramakrishna</dc:creator>
<dc:creator>Vincent Bayle</dc:creator>
<dc:creator>Linnka Lefebvre-Legendre</dc:creator>
<dc:creator>Stéphane Claverol</dc:creator>
<dc:creator>Matej Zabrady</dc:creator>
<dc:creator>Pascal G P Martin</dc:creator>
<dc:creator>Wolfgang Busch</dc:creator>
<dc:creator>Marie Barberon</dc:creator>
<dc:creator>Jens Tilsner</dc:creator>
<dc:creator>Yrjö Helariutta</dc:creator>
<dc:creator>Eugenia Russinova</dc:creator>
<dc:creator>Antoine Taly</dc:creator>
<dc:creator>Yvon Jaillais</dc:creator>
<dc:creator>Emmanuelle M Bayer</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Plasmodesmata act as unconventional membrane contact sites regulating intercellular molecular exchange in plants</dc:title>
<dc:identifier>pmid:39983675</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.034</dc:identifier>
</item>
<item>
<title>Advances in the study and treatment of genetic cardiomyopathies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39983674/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>Cardiomyopathies are primary disorders of the heart muscle. Three key phenotypes have been defined, based on morphology and arrhythmia burden: hypertrophic cardiomyopathy (HCM), with thickened heart muscle and diastolic dysfunction; dilated cardiomyopathy (DCM), with left ventricular enlargement and systolic dysfunction; and arrhythmogenic cardiomyopathy (ACM), with right, left, or biventricular involvement and arrhythmias out of proportion to systolic dysfunction. Genetic discoveries of the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 20;188(4):901-918. doi: 10.1016/j.cell.2025.01.011.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiomyopathies are primary disorders of the heart muscle. Three key phenotypes have been defined, based on morphology and arrhythmia burden: hypertrophic cardiomyopathy (HCM), with thickened heart muscle and diastolic dysfunction; dilated cardiomyopathy (DCM), with left ventricular enlargement and systolic dysfunction; and arrhythmogenic cardiomyopathy (ACM), with right, left, or biventricular involvement and arrhythmias out of proportion to systolic dysfunction. Genetic discoveries of the molecular basis of disease are paving the way for greater precision in diagnosis and management and revealing mechanisms that account for distinguishing clinical features. This deeper understanding has propelled the development of new treatments for cardiomyopathies: disease-specific, mechanistically based medicines that counteract pathophysiology, and emergent gene therapies that aim to intercept disease progression and restore cardiac physiology. Together, these discoveries have advanced fundamental insights into cardiac biology and herald a new era for patients with cardiomyopathy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39983674/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39983674</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.011>10.1016/j.cell.2025.01.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39983674</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Victoria N Parikh</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Eric D Adler</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Christine E Seidman</dc:creator>
<dc:creator>Carolyn Y Ho</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Advances in the study and treatment of genetic cardiomyopathies</dc:title>
<dc:identifier>pmid:39983674</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.011</dc:identifier>
</item>
<item>
<title>Cellular responses to RNA damage</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39983673/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>RNA plays a central role in protein biosynthesis and performs diverse regulatory and catalytic functions, making it essential for all processes of life. Like DNA, RNA is constantly subjected to damage from endogenous and environmental sources. However, while the DNA damage response has been extensively studied, it was long assumed that RNA lesions are relatively inconsequential due to the transient nature of most RNA molecules. Here, we review recent studies that challenge this view by revealing...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 20;188(4):885-900. doi: 10.1016/j.cell.2025.01.005.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RNA plays a central role in protein biosynthesis and performs diverse regulatory and catalytic functions, making it essential for all processes of life. Like DNA, RNA is constantly subjected to damage from endogenous and environmental sources. However, while the DNA damage response has been extensively studied, it was long assumed that RNA lesions are relatively inconsequential due to the transient nature of most RNA molecules. Here, we review recent studies that challenge this view by revealing complex RNA damage responses that determine survival when cells are exposed to nucleic acid-damaging agents and promote the resolution of RNA lesions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39983673/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39983673</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.005>10.1016/j.cell.2025.01.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39983673</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Jacqueline Cordes</dc:creator>
<dc:creator>Shubo Zhao</dc:creator>
<dc:creator>Carla M Engel</dc:creator>
<dc:creator>Julian Stingele</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Cellular responses to RNA damage</dc:title>
<dc:identifier>pmid:39983673</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.005</dc:identifier>
</item>
<item>
<title>Solute carriers: The gatekeepers of metabolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39983672/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>Solute carrier (SLC) proteins play critical roles in maintaining cellular and organismal homeostasis by transporting small molecules and ions. Despite a growing body of research over the past decade, physiological substrates and functions of many SLCs remain elusive. This perspective outlines key challenges in studying SLC biology and proposes an evidence-based framework for defining SLC substrates. To accelerate the deorphanization process, we explore systematic technologies, including human...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 20;188(4):869-884. doi: 10.1016/j.cell.2025.01.015.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Solute carrier (SLC) proteins play critical roles in maintaining cellular and organismal homeostasis by transporting small molecules and ions. Despite a growing body of research over the past decade, physiological substrates and functions of many SLCs remain elusive. This perspective outlines key challenges in studying SLC biology and proposes an evidence-based framework for defining SLC substrates. To accelerate the deorphanization process, we explore systematic technologies, including human genetics, biochemistry, and computational and structural approaches. Finally, we suggest directions to better understand SLC functions beyond substrate identification in physiology and disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39983672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39983672</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.015>10.1016/j.cell.2025.01.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39983672</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Artem Khan</dc:creator>
<dc:creator>Yuyang Liu</dc:creator>
<dc:creator>Mark Gad</dc:creator>
<dc:creator>Timothy C Kenny</dc:creator>
<dc:creator>Kıvanç Birsoy</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Solute carriers: The gatekeepers of metabolism</dc:title>
<dc:identifier>pmid:39983672</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.015</dc:identifier>
</item>
<item>
<title>Correction to: 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39982387/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 21:ehaf079. doi: 10.1093/eurheartj/ehaf079. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39982387/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39982387</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf079>10.1093/eurheartj/ehaf079</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39982387</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:date>2025-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)</dc:title>
<dc:identifier>pmid:39982387</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf079</dc:identifier>
</item>
<item>
<title>Titanium-nitride-oxide-coated vs. drug-eluting stents in acute coronary syndromes: an individual patient data meta-analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39981941/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In ACS patients, TiNOS was associated with similar rates of MACE and TLR as compared with DES but significantly lower rates of CD, MI, and stent thrombosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 21:ehaf098. doi: 10.1093/eurheartj/ehaf098. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: In acute coronary syndromes (ACS), vascular healing at the site of implantation of drug-eluting stents (DES) can be delayed. Titanium-nitride-oxide-coated stents (TiNOS) demonstrate faster strut coverage without the excessive intimal hyperplasia observed with bare metal stents. The 5-year outcomes of patients presenting with ACS, randomized to receive either TiNOS or DES, were compared.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A systematic review and individual participant data meta-analysis of trials comparing TiNOS with DES for the treatment of ACS was conducted (PROSPERO: CRD42024514342). The primary endpoint was major adverse cardiac events (MACE) at 5 years, a composite of cardiac death (CD), myocardial infarction (MI), and ischaemia-driven target lesion revascularization (TLR). Pre-specified secondary endpoints included CD, MI, TLR, and stent thrombosis. Data were pooled using a mixed-effects Cox regression model with random slope and stratified baseline hazards.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Patient-level data (n = 2743) were obtained from three randomized controlled trials (TiNOS: n = 1620 vs. DES: n = 1123). After a median follow-up of 4.93 years, there was no significant difference in the primary endpoint between TiNOS and DES (12.6% vs. 16.2%; hazard ratio [HR] .82, 95% confidence interval [CI] .67-1.00, P = .051), mainly due to a similar rate of TLR (8.0% vs. 8.1%; HR 1.05, 95% CI .80-1.38, P = .733). However, TiNOS was associated with significantly lower rates of CD (1.5% vs. 3.7%; HR .46, 95% CI .26-.81, P = .007), MI (5.2% vs. 9.6%; HR .56, 95% CI .42-.75, P &lt; .001), and stent thrombosis (1.1% vs. 3.8%; HR .30, 95% CI .17-.53, P &lt; .001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In ACS patients, TiNOS was associated with similar rates of MACE and TLR as compared with DES but significantly lower rates of CD, MI, and stent thrombosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39981941/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39981941</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf098>10.1093/eurheartj/ehaf098</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39981941</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Thabo Mahendiran</dc:creator>
<dc:creator>Frederic Bouisset</dc:creator>
<dc:creator>Pim Tonino</dc:creator>
<dc:creator>Nico H J Pijls</dc:creator>
<dc:creator>Jussi Sia</dc:creator>
<dc:creator>Kari Kervinen</dc:creator>
<dc:creator>Fernando Rivero-Crespo</dc:creator>
<dc:creator>Peter Jüni</dc:creator>
<dc:creator>Bruno Roza da Costa</dc:creator>
<dc:creator>Carlos Collet</dc:creator>
<dc:creator>Takuya Mizukami</dc:creator>
<dc:creator>Pasi Karjalainen</dc:creator>
<dc:creator>Bernard De Bruyne</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Titanium-nitride-oxide-coated vs. drug-eluting stents in acute coronary syndromes: an individual patient data meta-analysis</dc:title>
<dc:identifier>pmid:39981941</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf098</dc:identifier>
</item>
<item>
<title>Atrial fibrillation catheter ablation, brain glymphatic function, and cognitive performance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39981927/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Brain glymphatic function measured by DTI-ALPS index was impaired in patients with AF, mediates the association between AF and cognitive decline, and was improved after ablation therapy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 21:ehaf036. doi: 10.1093/eurheartj/ehaf036. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: It remains unknown whether the brain glymphatic system, which is driven by the heartbeat-driven pulsation of arteries and is responsible for cerebral waste clearance, is impaired in atrial fibrillation (AF) and mediates cognitive dysfunction related to AF. The aim of this study was to assess brain glymphatic alterations in AF, their role in cognitive function, and whether catheter ablation can improve glymphatic activity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this case-control and prospective before-and-after study, patients with AF and healthy controls (HCs) were enrolled. Participants underwent brain magnetic resonance imaging and a comprehensive neuropsychological battery. Glymphatic activity was quantified by diffusion tensor image analysis along the perivascular space (DTI-ALPS) index. Magnetic resonance imaging was repeated after surgery in patients who underwent ablation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 87 patients with AF and 44 HCs were enrolled. Compared with HCs, patients with AF had a lower ALPS index (P = .016). Nonparoxysmal AF patients showed lower ALPS index than both HCs (P = .002) and paroxysmal AF patients (P = .044). A lower ALPS index was associated with worse scores of Trail Making Test, Digit Symbol Substitution Test, Digit Span Test, and Stroop Colour and Word Test (all P &lt; .05). Mediation analyses revealed that glymphatic activity was a mediator between AF and cognitive decline. Among the 50 patients who underwent ablation therapy, DTI-ALPS index was improved after surgery (P = .015).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Brain glymphatic function measured by DTI-ALPS index was impaired in patients with AF, mediates the association between AF and cognitive decline, and was improved after ablation therapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39981927/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39981927</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf036>10.1093/eurheartj/ehaf036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39981927</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Jiahuan Guo</dc:creator>
<dc:creator>Zhe Zhang</dc:creator>
<dc:creator>Xu Meng</dc:creator>
<dc:creator>Jing Jing</dc:creator>
<dc:creator>Yiran Hu</dc:creator>
<dc:creator>Yan Yao</dc:creator>
<dc:creator>Ligang Ding</dc:creator>
<dc:creator>Lihui Zheng</dc:creator>
<dc:creator>Xingquan Zhao</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atrial fibrillation catheter ablation, brain glymphatic function, and cognitive performance</dc:title>
<dc:identifier>pmid:39981927</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf036</dc:identifier>
</item>
<item>
<title>Individual patient data meta-analysis of paclitaxel-coated balloons vs. drug-eluting stents for small-vessel coronary artery disease: the ANDROMEDA study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39981922/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients undergoing PCI for de novo SV-CAD, PCB angioplasty is associated with a reduction in MACE and a non-significant difference in TLF at 3 year follow-up compared with DES implantation. The restriction of the comparator group to second-generation DES does not alter the main conclusions. Larger trials comparing contemporary devices at a more prolonged follow-up are warranted to confirm these findings.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 21:ehaf002. doi: 10.1093/eurheartj/ehaf002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: In randomized clinical trials of patients undergoing percutaneous coronary intervention (PCI) for de novo small-vessel coronary artery disease (SV-CAD), paclitaxel-coated balloon (PCB) angioplasty showed mid-term angiographic or clinical non-inferiority to drug-eluting stent (DES) implantation. Nevertheless, these trials have sample size limitations, and the relative safety and efficacy beyond the first year remain uncertain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The ANDROMEDA study was a collaborative, investigator-initiated, individual patient data meta-analysis comparing 3 year clinical outcomes between PCB angioplasty and DES implantation for the treatment of de novo SV-CAD. Multiple electronic databases (PubMed, Scopus, ScienceDirect, and Web of Science) were searched from May 2010 to June 2024 to identify eligible trials. All the following eligibility criteria were required: (i) random allocations of treatments; (ii) patients with SV-CAD; (iii) treatment with PCB or DES; and (iv) clinical follow-up of at least 36 months. The primary and co-primary endpoints were major adverse cardiac events (MACE) and target lesion failure (TLF), respectively. The protocol was registered with PROSPERO (CRD42023479035).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Individual patient data from three randomized trials, including a total of 1154 patients and 1360 lesions, were combined. At 3 years, PCB was associated with a lower risk of MACE compared with DES [hazard ratio (HR) 0.67, 95% confidence interval (CI) 0.47-0.96], due to a lower risk of myocardial infarction and target vessel revascularization. This benefit persisted after multivariable adjustment (HR 0.75, 95% CI 0.58-0.96), but did not reach statistical significance in the two-stage analysis (HR 0.67, 95% CI 0.43-1.04). At the landmark analysis, the risk of MACE between groups was consistent over time. At 3 years, TLF was not significantly different between PCB and DES groups. Reconstructed time-to-event information from a fourth trial was included in a sensitivity analysis (1384 patients and 1590 lesions), showing consistent results in terms of TLF (HR 0.87, 95% CI 0.63-1.20). The comparison between PCB and second-generation DES did not reveal significant differences in 3 year TLF (HR 1.03, 95% CI 0.70-1.50).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients undergoing PCI for de novo SV-CAD, PCB angioplasty is associated with a reduction in MACE and a non-significant difference in TLF at 3 year follow-up compared with DES implantation. The restriction of the comparator group to second-generation DES does not alter the main conclusions. Larger trials comparing contemporary devices at a more prolonged follow-up are warranted to confirm these findings.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39981922/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39981922</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf002>10.1093/eurheartj/ehaf002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39981922</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Simone Fezzi</dc:creator>
<dc:creator>Daniele Giacoppo</dc:creator>
<dc:creator>Gregor Fahrni</dc:creator>
<dc:creator>Azeem Latib</dc:creator>
<dc:creator>Fernando Alfonso</dc:creator>
<dc:creator>Antonio Colombo</dc:creator>
<dc:creator>Felix Mahfoud</dc:creator>
<dc:creator>Bruno Scheller</dc:creator>
<dc:creator>Raban Jeger</dc:creator>
<dc:creator>Bernardo Cortese</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Individual patient data meta-analysis of paclitaxel-coated balloons vs. drug-eluting stents for small-vessel coronary artery disease: the ANDROMEDA study</dc:title>
<dc:identifier>pmid:39981922</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf002</dc:identifier>
</item>
<item>
<title>Gene therapy targeting INa to treat life-threatening arrhythmias: beyond proof-of-concept?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39981909/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 21:ehae930. doi: 10.1093/eurheartj/ehae930. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39981909/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39981909</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae930>10.1093/eurheartj/ehae930</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39981909</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Patrick Lugenbiel</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Gene therapy targeting INa to treat life-threatening arrhythmias: beyond proof-of-concept?</dc:title>
<dc:identifier>pmid:39981909</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae930</dc:identifier>
</item>
<item>
<title>Taking out the trash: the role of glymphatic function in cognitive function in patients with atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39981908/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 21:ehaf040. doi: 10.1093/eurheartj/ehaf040. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39981908/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39981908</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf040>10.1093/eurheartj/ehaf040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39981908</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>T Jared Bunch</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Taking out the trash: the role of glymphatic function in cognitive function in patients with atrial fibrillation</dc:title>
<dc:identifier>pmid:39981908</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf040</dc:identifier>
</item>
<item>
<title>The growing relevance of sex-specific risk factors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39980454/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 21;46(8):673-676. doi: 10.1093/eurheartj/ehaf021.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39980454/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39980454</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf021>10.1093/eurheartj/ehaf021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39980454</guid>
<pubDate>Fri, 21 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2025-02-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The growing relevance of sex-specific risk factors</dc:title>
<dc:identifier>pmid:39980454</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf021</dc:identifier>
</item>
<item>
<title>SecY translocon chaperones protein folding during membrane protein insertion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39978345/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>The Sec translocon is vital for guiding membrane protein insertion into lipid bilayers. The insertion and folding processes of membrane proteins are poorly understood. Here, we report cryo-electron microscopy structures of multi-spanning membrane proteins inserting through the SecY channel, the Sec translocon in prokaryotes. The high-resolution structures illustrate how bulky amino acids pass the narrow channel restriction. Comparison of different translocation states reveals that the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 12:S0092-8674(25)00106-0. doi: 10.1016/j.cell.2025.01.037. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The Sec translocon is vital for guiding membrane protein insertion into lipid bilayers. The insertion and folding processes of membrane proteins are poorly understood. Here, we report cryo-electron microscopy structures of multi-spanning membrane proteins inserting through the SecY channel, the Sec translocon in prokaryotes. The high-resolution structures illustrate how bulky amino acids pass the narrow channel restriction. Comparison of different translocation states reveals that the cytoplasmic and extracellular cavities of the channel create distinct environments for promoting the unfolding and folding of transmembrane segments (TMs), respectively. Released substrate TMs are either flexible or stabilized by an unexpected hydrophilic groove between TM3 and TM4 of SecY. Disruption of the groove causes global defects in the folding of the membrane proteome. These findings demonstrate that beyond its role as a passive protein-conducting channel, the SecY translocon actively serves as a chaperone, employing multiple mechanisms to promote membrane protein insertion and folding.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39978345/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39978345</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.037>10.1016/j.cell.2025.01.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39978345</guid>
<pubDate>Thu, 20 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Xiaomin Ou</dc:creator>
<dc:creator>Chengying Ma</dc:creator>
<dc:creator>Dongjie Sun</dc:creator>
<dc:creator>Jinkun Xu</dc:creator>
<dc:creator>Yang Wang</dc:creator>
<dc:creator>Xiaofei Wu</dc:creator>
<dc:creator>Dali Wang</dc:creator>
<dc:creator>Song Yang</dc:creator>
<dc:creator>Ning Gao</dc:creator>
<dc:creator>Chen Song</dc:creator>
<dc:creator>Long Li</dc:creator>
<dc:date>2025-02-20</dc:date>
<dc:source>Cell</dc:source>
<dc:title>SecY translocon chaperones protein folding during membrane protein insertion</dc:title>
<dc:identifier>pmid:39978345</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.037</dc:identifier>
</item>
<item>
<title>Motor and vestibular signals in the visual cortex permit the separation of self versus externally generated visual motion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39978344/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>Knowing whether we are moving or something in the world is moving around us is possibly the most critical sensory discrimination we need to perform. How the brain and, in particular, the visual system solves this motion-source separation problem is not known. Here, we find that motor, vestibular, and visual motion signals are used by the mouse primary visual cortex (VISp) to differentially represent the same visual flow information according to whether the head is stationary or experiencing...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 14:S0092-8674(25)00101-1. doi: 10.1016/j.cell.2025.01.032. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Knowing whether we are moving or something in the world is moving around us is possibly the most critical sensory discrimination we need to perform. How the brain and, in particular, the visual system solves this motion-source separation problem is not known. Here, we find that motor, vestibular, and visual motion signals are used by the mouse primary visual cortex (VISp) to differentially represent the same visual flow information according to whether the head is stationary or experiencing passive versus active translation. During locomotion, we find that running suppresses running-congruent translation input and that translation signals dominate VISp activity when running and translation speed become incongruent. This cross-modal interaction between the motor and vestibular systems was found throughout the cortex, indicating that running and translation signals provide a brain-wide egocentric reference frame for computing the internally generated and actual speed of self when moving through and sensing the external world.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39978344/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39978344</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.032>10.1016/j.cell.2025.01.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39978344</guid>
<pubDate>Thu, 20 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Mateo Vélez-Fort</dc:creator>
<dc:creator>Lee Cossell</dc:creator>
<dc:creator>Laura Porta</dc:creator>
<dc:creator>Claudia Clopath</dc:creator>
<dc:creator>Troy W Margrie</dc:creator>
<dc:date>2025-02-20</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Motor and vestibular signals in the visual cortex permit the separation of self versus externally generated visual motion</dc:title>
<dc:identifier>pmid:39978344</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.032</dc:identifier>
</item>
<item>
<title>Contextual computation by competitive protein dimerization networks</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39978343/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>Many biological signaling pathways employ proteins that competitively dimerize in diverse combinations. These dimerization networks can perform biochemical computations in which the concentrations of monomer inputs determine the concentrations of dimer outputs. Despite their prevalence, little is known about the range of input-output computations that dimerization networks can perform and how it depends on network size and connectivity. Using a systematic computational approach, we demonstrate...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 11:S0092-8674(25)00105-9. doi: 10.1016/j.cell.2025.01.036. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Many biological signaling pathways employ proteins that competitively dimerize in diverse combinations. These dimerization networks can perform biochemical computations in which the concentrations of monomer inputs determine the concentrations of dimer outputs. Despite their prevalence, little is known about the range of input-output computations that dimerization networks can perform and how it depends on network size and connectivity. Using a systematic computational approach, we demonstrate that even small dimerization networks of 3-6 monomers are expressive, performing diverse multi-input computations. Further, dimerization networks are versatile, performing different computations when their protein components are expressed at different levels, such as in different cell types. Remarkably, individual networks with random interaction affinities, when large enough, can perform nearly all potential one-input network computations merely by tuning their monomer expression levels. Thus, even the simple process of competitive dimerization provides a powerful architecture for multi-input, cell-type-specific signal processing.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39978343/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39978343</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.036>10.1016/j.cell.2025.01.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39978343</guid>
<pubDate>Thu, 20 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Jacob Parres-Gold</dc:creator>
<dc:creator>Matthew Levine</dc:creator>
<dc:creator>Benjamin Emert</dc:creator>
<dc:creator>Andrew Stuart</dc:creator>
<dc:creator>Michael B Elowitz</dc:creator>
<dc:date>2025-02-20</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Contextual computation by competitive protein dimerization networks</dc:title>
<dc:identifier>pmid:39978343</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.036</dc:identifier>
</item>
<item>
<title>Priorities for medical device regulatory approval: a report from the European Society of Cardiology Cardiovascular Round Table</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39977258/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>The European Union (EU) Medical Device Regulation increased regulatory scrutiny to improve the safety and performance of new medical devices. An equally important goal is providing timely access to innovative devices to benefit patient care. The European Society of Cardiology strongly advocates for the evolution of the Medical Device Regulation system to facilitate priority access for innovative devices for unmet needs and orphan cardiovascular (CV) medical devices in EU countries. Although...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 20:ehaf069. doi: 10.1093/eurheartj/ehaf069. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The European Union (EU) Medical Device Regulation increased regulatory scrutiny to improve the safety and performance of new medical devices. An equally important goal is providing timely access to innovative devices to benefit patient care. The European Society of Cardiology strongly advocates for the evolution of the Medical Device Regulation system to facilitate priority access for innovative devices for unmet needs and orphan cardiovascular (CV) medical devices in EU countries. Although device approval is currently executed by Notified Bodies in the EU, it will be advantageous in the mid-term to consider a single EU regulatory agency for devices. In the short term, steps can be taken to transform the current system into a more efficient, predictable, cost-effective, and user-friendly service. Key strategies include the following: enhancing predictability of the approval process through use of early scientific advice from regulators; establishing unique regulatory pathways for CV orphan, paediatric, and innovative devices; promoting more efficient (re)certification of essential legacy CV devices; improving transparency of sponsor interactions with Notified Bodies; expanding the roles of the Expert Panels to assist in the approval of CV devices; promoting global regulatory harmonization, considering streamlined authorization of CV medical technologies across selected jurisdictions; developing an efficient system to monitor device safety; and ensuring funding for data collection platforms. Some strategies that could help include considering a pilot programme for joint approval processes of selected devices in partnership with other regions (i.e. US Food and Drug Administration); developing priority pathways for accelerated access to innovative or orphan devices; and increasing recognition of the importance of early feasibility studies in the EU.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39977258/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39977258</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf069>10.1093/eurheartj/ehaf069</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39977258</guid>
<pubDate>Thu, 20 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Alan G Fraser</dc:creator>
<dc:creator>Piotr Szymanski</dc:creator>
<dc:creator>Martine Gilard</dc:creator>
<dc:creator>Thomas F Lüscher</dc:creator>
<dc:creator>Leila Abid</dc:creator>
<dc:creator>John Brennan</dc:creator>
<dc:creator>Robert Byrne</dc:creator>
<dc:creator>Lia Crotti</dc:creator>
<dc:creator>Inga Drossart</dc:creator>
<dc:creator>Jennifer Franke</dc:creator>
<dc:creator>Mario Gabrielli Cossellu</dc:creator>
<dc:creator>Ajay J Kirtane</dc:creator>
<dc:creator>Jana Kurucova</dc:creator>
<dc:creator>Mitchell Krucoff</dc:creator>
<dc:creator>Gearóid McGauran</dc:creator>
<dc:creator>Patrick O Myers</dc:creator>
<dc:creator>Donal B O'Connor</dc:creator>
<dc:creator>Radosław Parma</dc:creator>
<dc:creator>Paul Piscoi</dc:creator>
<dc:creator>Archana Rao</dc:creator>
<dc:creator>Andrea Rappagliosi</dc:creator>
<dc:creator>Giulio Stefanini</dc:creator>
<dc:creator>Eigil Samset</dc:creator>
<dc:creator>Alphons Vincent</dc:creator>
<dc:creator>Ralph Stephan von Bardeleben</dc:creator>
<dc:creator>Franz Weidinger</dc:creator>
<dc:date>2025-02-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Priorities for medical device regulatory approval: a report from the European Society of Cardiology Cardiovascular Round Table</dc:title>
<dc:identifier>pmid:39977258</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf069</dc:identifier>
</item>
<item>
<title>Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39976316/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>This American Heart Association/American College of Cardiology scientific statement on clinical considerations for competitive sports participation for athletes with cardiovascular abnormalities or diseases is organized into 11 distinct sections focused on sports-specific topics or disease processes that are relevant when considering the potential risks of adverse cardiovascular events, including sudden cardiac arrest, during competitive sports participation. Task forces comprising international...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 20:S0735-1097(24)10722-X. doi: 10.1016/j.jacc.2024.12.025. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This American Heart Association/American College of Cardiology scientific statement on clinical considerations for competitive sports participation for athletes with cardiovascular abnormalities or diseases is organized into 11 distinct sections focused on sports-specific topics or disease processes that are relevant when considering the potential risks of adverse cardiovascular events, including sudden cardiac arrest, during competitive sports participation. Task forces comprising international experts in sports cardiology and the respective topics covered were assigned to each section and prepared specific clinical considerations tables for practitioners to reference. Comprehensive literature review and an emphasis on shared decision-making were integral in the writing of all clinical considerations presented.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39976316/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39976316</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.025>10.1016/j.jacc.2024.12.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39976316</guid>
<pubDate>Thu, 20 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Jonathan H Kim</dc:creator>
<dc:creator>Aaron L Baggish</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Elizabeth H Dineen</dc:creator>
<dc:creator>J Sawalla Guseh Ii</dc:creator>
<dc:creator>Andre La Gerche</dc:creator>
<dc:creator>Rachel Lampert</dc:creator>
<dc:creator>Matthew W Martinez</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:creator>Dermot M Phelan</dc:creator>
<dc:creator>Keri M Shafer</dc:creator>
<dc:creator>American Heart Association Leadership Committee of the Council on Clinical Cardiology</dc:creator>
<dc:creator>Council on Basic Cardiovascular Sciences</dc:creator>
<dc:creator>Council on Cardiovascular and Stroke Nursing</dc:creator>
<dc:creator>Council on Cardiovascular Surgery and Anesthesia</dc:creator>
<dc:creator>Council on Peripheral Vascular Disease</dc:creator>
<dc:creator>American College of Cardiology</dc:creator>
<dc:creator>Larry A Allen</dc:creator>
<dc:creator>Mats Börjesson</dc:creator>
<dc:creator>Alan C Braverman</dc:creator>
<dc:creator>Julie A Brothers</dc:creator>
<dc:creator>Silvia Castelletti</dc:creator>
<dc:creator>Eugene H Chung</dc:creator>
<dc:creator>Timothy W Churchill</dc:creator>
<dc:creator>Guido Claessen</dc:creator>
<dc:creator>Flavio D'Ascenzi</dc:creator>
<dc:creator>Douglas Darden</dc:creator>
<dc:creator>Peter N Dean</dc:creator>
<dc:creator>Neal W Dickert</dc:creator>
<dc:creator>Jonathan A Drezner</dc:creator>
<dc:creator>Katherine E Economy</dc:creator>
<dc:creator>Thijs M H Eijsvogels</dc:creator>
<dc:creator>Michael S Emery</dc:creator>
<dc:creator>Susan P Etheridge</dc:creator>
<dc:creator>Sabiha Gati</dc:creator>
<dc:creator>Belinda Gray</dc:creator>
<dc:creator>Martin Halle</dc:creator>
<dc:creator>Kimberly G Harmon</dc:creator>
<dc:creator>Jeffrey J Hsu</dc:creator>
<dc:creator>Richard J Kovacs</dc:creator>
<dc:creator>Sheela Krishnan</dc:creator>
<dc:creator>Mark S Link</dc:creator>
<dc:creator>Martin Maron</dc:creator>
<dc:creator>Silvana Molossi</dc:creator>
<dc:creator>Antonio Pelliccia</dc:creator>
<dc:creator>Jack C Salerno</dc:creator>
<dc:creator>Ankit B Shah</dc:creator>
<dc:creator>Sanjay Sharma</dc:creator>
<dc:creator>Tamanna K Singh</dc:creator>
<dc:creator>Katie M Stewart</dc:creator>
<dc:creator>Paul D Thompson</dc:creator>
<dc:creator>Meagan M Wasfy</dc:creator>
<dc:creator>Matthias Wilhelm</dc:creator>
<dc:date>2025-02-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology</dc:title>
<dc:identifier>pmid:39976316</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.025</dc:identifier>
</item>
<item>
<title>Fast Degradation of MecciRNAs by SUPV3L1/ELAC2 Provides a Novel Opportunity to Tackle Heart Failure With Exogenous MecciRNA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39973625/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study demonstrates the fast degradation of mecciRNAs and the associated regulations of mitochondrial reactive oxygen species release of mitochondrial permeability transition pore by mecciRNAs. HF conditions lead to dysregulated mecciRNA degradation, and exogenous mecciRNAs demonstrate treatment potential in mouse models of HF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 20. doi: 10.1161/CIRCULATIONAHA.124.070840. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Circular RNAs derived from both nuclear and mitochondrial genomes are identified in animal cells. Mitochondria-encoded circular RNAs (mecciRNAs) are attracting more attention, and several members of mecciRNAs have already been recognized in regulating mitochondrial functions. Mitochondria dysfunctions are well-known to participate in heart failure (HF). This study was designed to investigate the RNA metabolism of mecciRNAs and the relevant roles and potential application of mecciRNAs in HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Compared with highly stable nuclear genome-encoded circular RNAs, the fast degradation feature of mecciRNAs is identified by RNA sequencing and a series of molecular, biochemical, and cellular experiments. The substantial protective effects of in vitro synthesized mecciRNAs were tested in both doxorubicin- and pressure overload-induced mouse models of HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We discover that mecciRNAs are promptly degraded by an animal-conserved complex of helicase SUPV3L1 (suppressor of var1, 3-like protein 1) and endoribonuclease ELAC2 (elaC ribonuclease Z 2). MecciRNA degradation complex and mecciRNAs interact with mitochondrial permeability transition pore and its regulators including TRAP1 (TNF receptor-associated protein 1) and CypD (cyclophilin D). MecciRNAs regulate mitochondrial levels of TRAP1 and CypD to modulate the opening of mitochondrial permeability transition pore and the release of mitochondrial reactive oxygen species. Exogenously applied mecciRNAs interact with cytosolic TRAP1 and increase mitochondrial levels of TRAP1, and lead to a more closed state of mitochondrial permeability transition pore to constrain deleterious reactive oxygen species release. HF conditions lead to stimulated mecciRNA degradation, and administration of in vitro synthesized mecciRNAs exhibits substantial protective effects in both doxorubicin- and pressure overload-induced mouse models of HF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study demonstrates the fast degradation of mecciRNAs and the associated regulations of mitochondrial reactive oxygen species release of mitochondrial permeability transition pore by mecciRNAs. HF conditions lead to dysregulated mecciRNA degradation, and exogenous mecciRNAs demonstrate treatment potential in mouse models of HF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39973625/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39973625</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070840>10.1161/CIRCULATIONAHA.124.070840</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39973625</guid>
<pubDate>Thu, 20 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Xu Liu</dc:creator>
<dc:creator>Qinwei Wang</dc:creator>
<dc:creator>Xinya Li</dc:creator>
<dc:creator>Yan Yang</dc:creator>
<dc:creator>Yuqi Deng</dc:creator>
<dc:creator>Xiaolin Wang</dc:creator>
<dc:creator>Peipei Wang</dc:creator>
<dc:creator>Liang Chen</dc:creator>
<dc:creator>Likun Ma</dc:creator>
<dc:creator>Ge Shan</dc:creator>
<dc:date>2025-02-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Fast Degradation of MecciRNAs by SUPV3L1/ELAC2 Provides a Novel Opportunity to Tackle Heart Failure With Exogenous MecciRNA</dc:title>
<dc:identifier>pmid:39973625</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070840</dc:identifier>
</item>
<item>
<title>Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39973614/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250224031514&amp;v=2.18.0.post9+e462414
      <description>This American Heart Association/American College of Cardiology scientific statement on clinical considerations for competitive sports participation for athletes with cardiovascular abnormalities or diseases is organized into 11 distinct sections focused on sports-specific topics or disease processes that are relevant when considering the potential risks of adverse cardiovascular events, including sudden cardiac arrest, during competitive sports participation. Task forces comprising international...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 20. doi: 10.1161/CIR.0000000000001297. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This American Heart Association/American College of Cardiology scientific statement on clinical considerations for competitive sports participation for athletes with cardiovascular abnormalities or diseases is organized into 11 distinct sections focused on sports-specific topics or disease processes that are relevant when considering the potential risks of adverse cardiovascular events, including sudden cardiac arrest, during competitive sports participation. Task forces comprising international experts in sports cardiology and the respective topics covered were assigned to each section and prepared specific clinical considerations tables for practitioners to reference. Comprehensive literature review and an emphasis on shared decision-making were integral in the writing of all clinical considerations presented.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39973614/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250224031514&v=2.18.0.post9+e462414">39973614</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001297>10.1161/CIR.0000000000001297</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39973614</guid>
<pubDate>Thu, 20 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Jonathan H Kim</dc:creator>
<dc:creator>Aaron L Baggish</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Elizabeth H Dineen</dc:creator>
<dc:creator>J Sawalla Guseh</dc:creator>
<dc:creator>Andre La Gerche</dc:creator>
<dc:creator>Rachel Lampert</dc:creator>
<dc:creator>Matthew W Martinez</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:creator>Dermot M Phelan</dc:creator>
<dc:creator>Keri M Shafer</dc:creator>
<dc:creator>American Heart Association Leadership Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Peripheral Vascular Disease; and American College of Cardiology</dc:creator>
<dc:date>2025-02-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology</dc:title>
<dc:identifier>pmid:39973614</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001297</dc:identifier>
</item>





























</channel>
</rss>